We are live on ! Find out more
GS

Gilead Sciences Portfolio holdings

AUM $2.12B
1-Year Est. Return 143.53%
This Fund
S&P 500
This Quarter Est. Return
+26.51%
1 Year Est. Return
+143.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.94B
AUM Growth
+$144M
Cap. Flow
-$85.8M
Cap. Flow %
-4.43%
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
–
Reduced
–
Closed
3

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$42.6M
2
TNGX icon
Tango Therapeutics
TNGX
+$40.8M
3
CYPH
Cypherpunk Technologies Inc
CYPH
+$2.41M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
1
Arcus Biosciences
RCUS
$3.4B
$749M 38.69%
31,424,760
– –
LKFT
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
$551M 28.45%
16,707,477
– –
ACLX
3
DELISTED
Arcellx
ACLX
$438M 22.64%
6,720,803
– –
ASMB icon
4
Assembly Biosciences
ASMB
$507M
$153M 7.92%
4,505,391
– –
KYTX icon
5
Kyverna Therapeutics
KYTX
$452M
$38.8M 2%
4,126,119
– –
XLO icon
6
Xilio Therapeutics
XLO
$59.2M
$5.83M 0.3%
650,389
– –
CYPH
7
Cypherpunk Technologies Inc
CYPH
$67.2M
– –
-5,319,148
Closed -$2.41M
MRUS
8
DELISTED
Merus
MRUS
– –
-452,527
Closed -$42.6M
TNGX icon
9
Tango Therapeutics
TNGX
$4.32B
– –
-4,854,443
Closed -$40.8M

Similar funds

BCM
Basswood Capital Management New York $2.12B AUM 19.53% 1-Year Est. Return
GHA
GW Henssler & Associates Kennesaw, Georgia $2.12B AUM 20.77% 1-Year Est. Return
IVAV
Index Venture Associates VI St. Helier, Channel Islands, Jersey $2.11B AUM 13.76% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
HJGA
Hardman Johnston Global Advisors Stamford, Connecticut $2.1B AUM 41.89% 1-Year Est. Return
CF
Centaurus Financial Anaheim, California $2.1B AUM 21.28% 1-Year Est. Return
BWC
Blue Whale Capital London, United Kingdom $2.1B AUM 97.03% 1-Year Est. Return
SFS
Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

Gilead Sciences's Q4 2025 Portfolio in Review

As of Q4 2025, Gilead Sciences held 9 positions worth $1.94B, up 8% from $1.79B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Gilead Sciences withdrew a net $85.8M in Q4 2025, closing 3 positions. Its most notable exit was Merus, an estimated $42.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Gilead Sciences fully exited Merus in Q4 2025, selling an estimated $42.6M.
  • Gilead Sciences's ten largest holdings make up 100% of its $1.94B portfolio in Q4 2025.
  • Gilead Sciences opened 0 new positions and closed 3 in Q4 2025.
  • Gilead Sciences's portfolio value rose 8% quarter-over-quarter to $1.94B.

Based on Gilead Sciences's 13F filing for Q4 2025, filed 12 Feb 2026.